Ankita Dhere* 1
Yogda Rawool 2
Neha Chavan 1
Amruta Patil 1
Harshada Patil 1
Tejashree Khamkar 1
3D printing in pharmaceuticals has been under vigorous research and developments ever since the beginning, with the first researches traced back to 1996 (Wu et al., 1996). But then, times have changed-a lot of things have changed very recently with the advent of commercial-scale capabilities [8]. Most of these earlier studies have focused on exploring different aspects of 3D printing technology suitable for pharmaceutical applications. Spritam®, the very first representative product to have been FDA commercialized and manufactured in a scale significant, evidences the potential of 3D printing technologies appear to be instrumental in allowing the manufacturing of drugs in large scales [9]. Generally, all 3D printing methods for developing pharmaceutical dosage forms can be classified into four major categories: extrusion-based, powder-based, liquid-based, and sheet lamination-based [10].
3DP, or three-dimensional printing, is the technology whereby different geometric shapes are created into 3D issues layer by layer. Major advantages of 3DP technologies over conventional processes are the making of complex and sophisticated solid dosage forms, efficient on-demand manufacture, and the ability to actually personalize pharmaceuticals with individually adjusted doses [11]. Currently, there is a high degree of interest in 3DP application in pharmaceuticals for innovative design of drug delivery systems and drug manufacturing [12]. Yet, the full deployment of 3DP technology in pharmaceuticals may be impeded by some technological advancements and legal problems, though it is clear that it reflects several possible medical and commercial benefits [13].
3D printing in pharmaceutical product design
The medicines meant for the animals are needed for the maintenance and restoration of health in mammals [14]. This medicine is obtained by making dosage forms available in various strengths as would be needed for administration as veterinary medicine: that these differences are among the particular-most pharmacokinetic variations that affect the composition and operation of veterinary dosage forms [15]. Generally, a dosage regimen is adjusted according to animal weight; thus, it is A drug often shows up in different strengths [16]. An important example of this is fluralaner, clindamycin hydrochloride, and mavacoxib [17]. But it is also an everyday practice where veterinarians and pet owners extract the whole tablets and divide it into 2 or 4 parts according to the need of their pets [18]. Like humans, animals have their own preference in the way they take medications. Therefore, considering animal preference is an important aspect in veterinary drug design [19]. For other species, take for example; horses are very fond of fruits (like apple) while dogs love eating animal proteins (like chicken, pig, and beef). To make it fit to the taste of dogs, Simparica Trio contains hydrolyzed vegetable protein, sweeteners, gelatin, and pork liver powder. Generally, nowadays most frequent doses given to animals are orally and parenterally given formulations. Advancement in pharmaceutical production has led to the manufacturing of many palatable oral dosage forms. Chewable tablets are still widely used in veterinary for pet applications, particularly cats and dogs. As a matter of fact, chewable tablets are the most commonly utilized pharmaceutical dosage form in veterinary care -more than in human medicine [20]. This puts into perspective the situation as regards chewable formulations for animal purposes in the market [21]. In fact, compared to human formulations more chewable veterinary formulations are marketed. Probably because the animal does this without luring anything into its mouth [22].
Fig.1. Target product profile of medicinal products intended to be used by dermatological patient
Patient Centric Pharmaceutical Drug Product Design:
The Impact on Adherence to Medication.
The Impact of Focused on patients Pharmaceutical Drug Product Design on Medication Persistence The core principle of PCDPD is to include patients' needs and preferences into the design of a medicinal product [23]. Only 45 studies examining patients' preferences for medications were found in a recent literature review. Only 35 of them focused into dosage form design, and 11 of them only evaluated oral dosage forms [24]. surprisingly, almost no study has examined at patients' preferences for the size, shape, and colour of solid dosage forms, which are frequently used for The foundation of PCDPD is to incorporate patients' requirements and preferences into the design of a medication [25]. Only 45 studies examining patients' preferences for medicinal mixtures were found in a recent review of the literature. Only 35 of them focused into dosage form design, and 11 of these only examined oral dosage forms. remarkably, not much research have looked at patients' preferences for the size, shape, and color of solid dosage forms, which are frequently utilized to treat non-communicable illnesses [26]. The pharmaceutical business is capable of developing and manufacturing a wide range of dosage forms as well as to traditional solid dosage forms like tablets [27]. Certain pharmaceutical goods become more popular as better NCD remedies when a PCDP design is used. The pharmaceutical sector is capable of producing a wide range of dosage forms as well as to traditional solid dosage forms such tablets. In the context of a PCDP-based product design, some dis-opy of drug products seem to emerge more favourably than others for promoting adherence, and these will be addressed in greater detail with more focus on their impact on adherence to medication.
Faster formulation development by formulation design.
The selection of excipients and the design of the tablet are complex and should be made with a proper understanding of the formulation. The excipients must exhibit performance characteristics expected, such as stability with the active pharmaceutical ingredient (API), ease of tableting, and the required disintegration rate [28]. The tablet structure may influence delivery of the desired pharmacokinetic profile. This phenomenon occurs in conventional as well as 3D printed tablets. Thus, in light of these factors, the newly devised 3D Printing Formulation by Design (3DFbD) came into being [29]. The best formulation among others can thus be achieved by considering tablet structure information in conjunction with the physicochemical and biopharma-ceutical characteristics of the API and excipients [30]. The formulation would thus be controlled based on physicochemical data that would decrease the uncertainty in the traditional formulation approaches. 3D printings work such that they can produce structures controlling the rate, duration, and mode of release. Therefore, the traditional empirical method gives way to a rational design based on the Formulation-by-Design process. This decides the necessary release mode, the start, and the rate of release through physiological parameters like GI transit time and site of absorption to assure knowledge of the amount of drug delivered at different times during absorption. The tablet design is to be selected from a comprehensive list of previously known tablet designs that provide the desired mode, rate, and time of onset of release [31]. In such a "stackable approach", tablet components are added toward tablet formation, just like Legos stack to create a structure. This allows for rather easy construction of tablet structures yielding complex release profiles. after the formation of the tablet structure, excipients with the necessary physicochemical properties to enable formulation and performance upon construction compatibility with API form pharmacological excipients and Generally Recognized as Safe (GRAS) substances. Once the structures and excipients have been determined, the computer codes will be drawn upon to print prototypes for rapid performance assessment both in vivo and in vitro. The designs can be modified within hours instead of days or weeks as required, owing to the dSemonstrated application in the in vitro release profile and the specific in vivo PKs using the 3DFbD® and 3D printing. Zheng et al. showed this potential realization of the target value in the in vitro release profile and PK results in vivo through application of 3DFbD and 3D printing to the molecule. Its overall tendency is oriented more favorably towards 3D printing technologies, as the release profile can be altered in a much accurate and precise way [32].
10.5281/zenodo.15237410